Free Trial

Xeris Biopharma Q2 2023 Earnings Report

Xeris Biopharma logo
$3.61 +0.15 (+4.34%)
As of 01/3/2025 05:39 PM Eastern

Xeris Biopharma EPS Results

Actual EPS
-$0.14
Consensus EPS
-$0.13
Beat/Miss
Missed by -$0.01
One Year Ago EPS
N/A

Xeris Biopharma Revenue Results

Actual Revenue
$38.01 million
Expected Revenue
$34.84 million
Beat/Miss
Beat by +$3.17 million
YoY Revenue Growth
N/A

Xeris Biopharma Announcement Details

Quarter
Q2 2023
Time
N/A

Conference Call Resources

Conference Call Audio

Xeris Biopharma Earnings Headlines

How this >10-cent coin is going to outperform Bitcoin
Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 different coins that have returned over 100%... But today, Chris is now making the biggest crypto call of his ENTIRE career…
Xeris Biopharma downgraded to Neutral from Overweight at Piper Sandler
Xeris Biopharma price target raised to $6.60 from $6 at H.C. Wainwright
See More Xeris Biopharma Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Xeris Biopharma? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Xeris Biopharma and other key companies, straight to your email.

About Xeris Biopharma

Xeris Biopharma (NASDAQ:XERS), a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome. It is also developing XP-8121, a once-weekly subcutaneous injection of levothyroxine that is in phase I clinical trial for the treatment of hypothyroidism; and non-aqueous XeriSol and XeriJect technologies for various therapies. The company was incorporated in 2005 and is headquartered in Chicago, Illinois.

View Xeris Biopharma Profile

More Earnings Resources from MarketBeat